TABLE 2.
Outcomes associated with the combination of vancomycin and beta-lactamsa
| Patient characteristic or outcome |
Value(s) |
|||||
|---|---|---|---|---|---|---|
| VPT (n = 366) |
VC (n= 1,734) |
Pb | VPT (n = 366) |
VM (n = 392) |
Pb | |
| No. (%) with any AKI | 144 (39.3) | 419 (24.2) | <0.0001 | 144 (39.3) | 92 (23.5) | <0.0001 |
| No. (%) with stage 2 AKI | 55 (15.0) | 101 (5.8) | <0.0001 | 55 (15.0) | 26 (6.6) | <0.0001 |
| No. (%) with stage 3 AKI | 24 (6.6) | 31 (1.8) | <0.0001 | 24 (6.6) | 5 (1.3) | <0.0001 |
| No. (%) with RRT | 4 (1.1) | 21 (1.2) | 1.000 | 4 (1.1) | 6 (1.5) | 0.754 |
| Day of AKI occurrence | 3.2 ± 2.6 | 2.6 ± 2.5 | 0.030 | 3.2 ± 2.6 | 2.2 ± 2.1 | 0.003 |
| ICU LOS, h [IQR] | 82.5 [46.74–151.0] | 94.0 [46.0–214.5] | <0.0001 | 82.5 [46.74–151.0] | 94.0 [53.0–210.75] | 0.001 |
| ICU LOS – AKI subgroup LOS | 93 [51–168] | 107 [58–223] | 0.013 | 93 [51–168] | 110 [60–220] | 0.058 |
| Hospital LOS, days [IQR] | 9.0 [6.0–17.0] | 9.0 [5.0–16.0] | 0.558 | 9.0 [6.0–17.0] | 10.0 [6–17.75] | 0.236 |
| No. (%) with hospital mortality | 42 (11.5) | 265 (15.3) | 0.061 | 42 (11.5) | 67 (17.1) | 0.028 |
| No. (%) with hospital mortality –no. (%) in AKI subgroup | 25 (17.4) | 111 (26.4) | 0.018 | 25 (17.4) | 26 (28.3) | 0.057 |
a
Abbreviations: AKI, acute kidney injury; ICU, intensive care unit; IQR, interquartile range; LOS, length of stay; OR, odds ratio; RRT, renal replacement therapy; VC, vancomycin plus cefepime; VM, vancomycin plus meropenem; VPT, vancomycin plus piperacillin-tazobactam.
b
P values are shown for comparisons made separately between VPT and VC (OR [95% CI], 2.04 [1.61 to 2.58]) and between VPT and VM (OR, 2.12 [1.61 to 2.90]). Unadjusted bivariate odds ratio values represent the primary outcome for any AKI. Comparisons were made separately between VPT and VC and between VPT and VM.